Randomized, placebo-controlled, double-blind phase 2 study of patritumab (U3-1287) in combination withcetuximab plus platinum-based therapy in first line setting in subjects with recurrent or metastatic squamous cell carcinoma of the head and neck - N/A

Daiichi Sankyo Pharma Development0 个研究点目标入组 105 人开始时间: 2016年5月30日最近更新: 2024年8月19日

适应症

试验速览

阶段: 2 期
状态: 招募中
发起方
入组人数: 105

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomized controlled study
盲法: Blinded (masking used)

入排标准

年龄范围: 18 Years 至 one（—）
性别: All

入选标准

•1. Adult subjects =18 years old
•2. Histologically confirmed recurrent disease or metastatic SCCHN tumor and/or from its lymph nodal metastases originating from the oral cavity, oropharynx, hypopharynx, and larynx
•3. Heregulin expression level is required
•- Samples must be taken from subjects who have recurrent or metastatic disease (rec/met). These samples can be from either rec/met archived or fresh biopsy samples (either primary tumor or metastases)
•- No cancer treatment between time of biopsy and submission of sample
•- Surgical or core needle biopsy is acceptable
•- Fine-needle aspiration or cytology is not acceptable for biopsies
•4. HPV status or p16 (surrogate for HPV) is required. These results must come from tumor tissue. These results may be obtained from either a local lab or samples sent to the central lab. HPV or p16 status can be from any tumor biopsy material from initial diagnosis
•5. Measurable disease per Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1
•6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
•7. Hematological function, as follows:
•- Absolute neutrophil count (ANC) = 1.5 x 109/L
•- Platelet count = 100 x 109/L
•- Hemoglobin = 10 g/dL
•8. Renal function, as follows:
•- Estimated serum creatinine clearance (mL/min) as an estimate of GFR = 60 mL/min for cisplatin and = 30 mL/min for carboplatin (Note: GFR will not be directly measured in this protocol)
•9. Hepatic function, as follows:
•- Aspartate aminotransferase (AST) = 2.5 x upper limit of normal (ULN) (if liver metastases are present, < 5 x ULN)
•- Alanine aminotransferase (ALT) = 2.5 x ULN (if liver metastases are present, < 5 x ULN)
•- Alkaline phosphatase = 2.0 x ULN (if bone or liver metastases are present, < 5 x ULN)
•- Bilirubin = 1.5 x ULN
•10. Prothrombin time or partial thromboplastin time = 1.5 x ULN
•11. Women of childbearing potential must have a negative serum pregnancy test performed within 14 days prior to enrollment (where demanded by local regulations, test may be required within 72 hours prior to enrollment)
•12. Adult subjects of child-bearing potential must agree to use double-barrier contraceptive measures. Two of the following precautions must be used: bilateral vasectomy, bilateral tubal ligation, intrauterine device (IUD), combined (estrogen and progesterone containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progesterone-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine hormone-releasing system (IUS), condom with spermicide, abstinence. These contraception measures must be used for the entire duration of the study and for 6 months after the last study dose is received-
•13. Subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
•14. Provided written informed consent(s)

排除标准

•1. Left ventricular ejection fraction (LVEF) <50%
•2. Prior EGFR targeted regimen
•3. No HRG expression result
•4. No HPV or p16 status
•5. Prior anti-HER3 therapy
•6. Prior chemotherapy for recurrent/metastatic disease
•7. Anti-cancer therapy between biopsy and submission of sample
•8. Presence of squamous cell tumors of the nasopharynx
•9. History of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease for = 2 years
•10. Known history of brain metastases or active brain metastases
•11. Uncontrolled hypertension (systolic > 160 mm Hg or diastolic > 100 mm Hg)
•12. Clinically significant electrocardiograph (ECG) findings
•13. Myocardial infarction within 1 year before enrollment, symptomatic congestive heart failure (New York Heart Association >Class II), unstable angina, or unstable cardiac arrhythmia requiring medication
•14. Platinum-containing drug therapy with radiotherapy less than 6 months before study drug treatment
•15. Therapeutic or palliative radiation therapy or major surgery within 4 weeks before study drug treatment. Radiation treatment to all sites of measureable disease unless progression is documented after radiation
•16. Participated in clinical drug trials within 4 weeks before study drug treatment.
•Current participation in other investigational procedures
•17. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, known HIV infection, or active hepatitis B or C infection or undergoing medical treatment for infection
•18. Uncontrolled type 1 or 2 diabetes mellitus
•19. Known hypersensitivity or allergic reaction against any of the components of the trial treatment
•20. Pregnant, breastfeeding, or unwilling/unable to use acceptable contraception
•21. Residual toxicities = Grade 1 from previous therapies that the Investigator determines would exclude participation
•22. Psychological, social, familial, or geographical factors that would interfere with study participation or follow-up
•23. Committed to an institution by virtue of an order issued either by judicial or administrative authorities
•24. Employee or immediate relative of an employee of the sponsor, CRO, the study center, or their affiliates or partners

研究者

发起方

Daiichi Sankyo Pharma Development

相似试验

进行中（未招募）

不适用

Abatacept treatment in primary Sjögrens SyndromePrimary Sjögren's syndrome (pSS)MedDRA version: 16.1Level: LLTClassification code 10042846Term: Syndrome Sjogren'sSystem Organ Class: 100000004859

EUCTR2014-000417-31-NLniversity Medical Center Groningen

进行中（未招募）

1 期

Randomized, double-blind, placebo-controlled phase II pilot study of the impact of mesalazine enemas on the mucosal gut flora in patients with inflammatory bowel disease - Impact of mesalazine vs placebo on mucosal gut flora in IBD patientsActive inflammatory bowel disease, i.e. either left-sided ulcerative colitis or Crohn´s Disease (Colon) with signs of inflammation within 40 cm ab ano.MedDRA version: 8.1Level: LLTClassification code 10021972Term: Inflammatory bowel disease

EUCTR2006-004162-13-DECharité Universitätsmedizin, Campus Charité Mitte40

已完成

3 期

Randomized, double-blind, placebo-controlled phase III study (ASAP III study) to assess the efficacy and safety of Abatacept treatment in patients with primary Sjögren*s syndrome (ASAP III study = Abatacept Sjögren Active Patients phase III study)primary Sjögren's syndrome10003816

NL-OMON44430niversitair Medisch Centrum Groningen80

进行中（未招募）

不适用

EUCTR2009-014725-16-DEAIO Studien gGmbH

已完成

3 期

Efficacy and safety of Octanorm in patients with dermatomyositisMusculoskeletal DiseasesDermatomyositis

ISRCTN11520709Octapharma Pharmazeutika Produktionsges.m.b.H.78